Shares shifted as Bloom Energy climbed 6.1% to $269.75 on Wednesday, with investors continuing to reprice the company's expanded partnership with Oracle and a related $400 million stock warrant — a deal that has fundamentally transformed how Wall Street views this fuel cell maker.
• A Single Customer Is Rewriting Bloom's Revenue Story. Under a master services agreement announced April 13, Oracle committed to procuring up to 2.8 gigawatts of Bloom's fuel cell systems, with an initial 1.2 GW already contracted and deploying.
Management subsequently raised 2026 revenue guidance to $3.4–$3.8 billion, roughly 80% year-over-year growth at the midpoint — up from $2.02 billion in 2025. The deal also includes full power for Oracle's Project Jupiter AI campus in New Mexico. For shareholders, the question is concentration risk: one hyperscaler now anchors a huge portion of the growth thesis.
• The $400 Million Warrant Creates a Built-In Cheerleader. Oracle received the right to purchase 3.53 million Bloom shares at $113.28 apiece — roughly $400 million total.
Oracle now has a direct financial interest in Bloom's stock price going up, since every new Oracle deal with Bloom potentially boosts revenue and drives the stock higher, making Oracle's warrant more valuable — an alignment that incentivizes deeper procurement but also raises questions about whether the partnership economics favor the buyer.
• The $20 Billion Backlog Number Deserves a Hard Look. Bloom reports a total backlog of roughly $20 billion with a product backlog of ~$6 billion, up 2.5x year-over-year. But a recent investigation flagged that Bloom's audited remaining performance obligations — the binding revenue measure under accounting rules — stood at just $441 million for products as of March 2026, an order of magnitude smaller than the marketed backlog.
Across comparable companies, the widest gap was about 2x; Bloom's is above 40x. Investors pricing off the headline number should understand what they're actually buying.
• Volatility Reflects a Stock That Has Outrun Most Analyst Targets. The Street's mean price target has more than doubled from ~$111 in December to $267 by late June , yet Bloom has routinely traded above it. At roughly 128x forward earnings and up ~250% year-to-date , the stock embeds years of flawless execution. Upcoming Q2 earnings on July 28 are expected to show EPS of $0.35, a 250% year-over-year jump — a number that must deliver to justify today's price.